Event

NVTx leaders featured in ETPN webinar on next-generation LNP technologies

Oct 4, 2024

NTx leaders featured in ETPN webinar: Advertisement featuring title, photos of three speakers, organizers' logos

NanoVation TherapeuticsTM co-founders Drs Pieter Cullis and Dominik Witzigmann were among the featured speakers in the webinar “Next Generation LNP Technologies for Extra-Hepatic Nucleic Acid Delivery,” delivered on 24 September 2024.

The session attracted over 600 registrants and showcased the latest advancements in LNP technologies with real-world applications. The speakers, who also included Dr. Laura Evgin (UBC), shared their insights into the future of RNA therapeutics and CAR-T cell therapies.

The event was co-organized by NanoVation TherapeuticsTM and the European Technology Platform on Nanomedicine (ETPN Association), an initiative led by industry since 2005 to advance the application of nanotechnology in healthcare. Stay tuned for more NVTxTM-ETPN collaborations!

Watch videos of the presentations by Drs Cullis & Witzigmann below.

Pieter Cullis (Co-Founder and Board Chair of NanoVation TherapeuticsTM) provides a historical perspective on the evolution of Lipid Nanoparticles (LNPs), showing how they’ve gone from research tools to life-saving medicines, including COVID-19 vaccines.

Property of the European Technology Platform on Nanomedicine (ETPN). Used with permission.

Dominik Witzigmann (Co-Founder and CEO of NanoVation TherapeuticsTM) discusses the next frontier in tissue-specific delivery, emphasizing that no “one-size-fits-all” solution exists for RNA delivery, which requires tailored LNP designs for different tissues.

Property of the European Technology Platform on Nanomedicine (ETPN). Used with permission.

Image of Dr. Cullis and his talk title "Presenting a historical perspective on LNPs"

Pieter Cullis (Co-Founder and Board Chair of NanoVation TherapeuticsTM) provides a historical perspective on the evolution of Lipid Nanoparticles (LNPs), showing how they’ve gone from research tools to life-saving medicines, including COVID-19 vaccines.

Property of the European Technology Platform on Nanomedicine (ETPN). Used with permission.

NTx CEO Domink Witzigmann smiles next to the title of his talk: presenting next-generation LNPs

Dominik Witzigmann (Co-Founder and CEO of NanoVation TherapeuticsTM) discusses the next frontier in tissue-specific delivery, emphasizing that no “one-size-fits-all” solution exists for RNA delivery, which requires tailored LNP designs for different tissues.

Property of the European Technology Platform on Nanomedicine (ETPN). Used with permission.